A226950 Stock Overview
A clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
OliX Pharmaceuticals, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩18,000.00 |
| 52 Week High | ₩32,750.00 |
| 52 Week Low | ₩8,280.00 |
| Beta | 0.73 |
| 1 Month Change | -2.76% |
| 3 Month Change | -6.93% |
| 1 Year Change | 25.96% |
| 3 Year Change | -56.10% |
| 5 Year Change | -15.09% |
| Change since IPO | -45.12% |
Recent News & Updates
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump
Dec 07
OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt
Nov 15OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Oct 09Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower
Aug 22Recent updates
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump
Dec 07OliX Pharmaceuticals (KOSDAQ:226950) Is Making Moderate Use Of Debt
Nov 15OliX Pharmaceuticals, Inc (KOSDAQ:226950) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Oct 09Market Cool On OliX Pharmaceuticals, Inc's (KOSDAQ:226950) Revenues Pushing Shares 27% Lower
Aug 22We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt
Jul 22It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks
Jun 25OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely
Apr 13Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year
Feb 17
Shareholder Returns
| A226950 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -11.1% | -1.2% | -0.9% |
| 1Y | 26.0% | 16.3% | -9.0% |
Return vs Industry: A226950 exceeded the KR Biotechs industry which returned 16.1% over the past year.
Return vs Market: A226950 exceeded the KR Market which returned -9% over the past year.
Price Volatility
| A226950 volatility | |
|---|---|
| A226950 Average Weekly Movement | 17.3% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A226950's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A226950's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 72 | Dong-Ki Lee | www.olixpharma.com |
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia.
OliX Pharmaceuticals, Inc Fundamentals Summary
| A226950 fundamental statistics | |
|---|---|
| Market cap | ₩310.29b |
| Earnings (TTM) | -₩25.30b |
| Revenue (TTM) | ₩16.14b |
19.2x
P/S Ratio-12.3x
P/E RatioIs A226950 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A226950 income statement (TTM) | |
|---|---|
| Revenue | ₩16.14b |
| Cost of Revenue | ₩245.39m |
| Gross Profit | ₩15.89b |
| Other Expenses | ₩41.19b |
| Earnings | -₩25.30b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47k |
| Gross Margin | 98.48% |
| Net Profit Margin | -156.78% |
| Debt/Equity Ratio | 269.0% |
How did A226950 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 12:55 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OliX Pharmaceuticals, Inc is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Taehee Kim | Mirae Asset Securities Co., Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |